Inovio pharmaceuticals, inc. (INO)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
ASSETS
Current assets:
Cash and cash equivalents

158,447

22,196

15,853

19,735

20,779

23,693

19,397

15,085

37,508

23,786

23,278

23,860

22,903

19,136

23,250

28,450

41,624

57,632

85,468

70,297

26,145

40,543

70,669

88,535

98,770

33,719

33,067

10,352

20,086

5,646

4,588

5,952

11,128

17,350

25,302

30,594

19,998

Short-term investments

111,550

67,338

77,945

86,235

107,216

57,538

66,096

80,509

75,259

103,638

118,611

68,138

66,755

85,629

96,435

106,082

105,163

105,357

85,313

84,295

54,866

53,075

30,259

20,322

18,011

18,905

13,104

13,107

7,978

8,034

10,554

13,487

13,730

12,863

5,763

5,759

1,846

Accounts receivable

641

700

776

130

2,783

3,316

2,831

1,712

5,147

6,003

6,237

7,522

9,864

15,821

17,455

10,365

11,152

7,299

10,965

5,608

3,299

2,804

1,621

2,876

2,699

3,301

10,574

540

1,029

830

481

432

876

467

426

347

32

Accounts receivable from affiliated entities

634

1,332

978

996

1,295

738

1,567

960

2,242

486

924

1,189

1,232

748

-

-

-

33

-

-

-

-

-

-

18

-

0

0

43

36

-

-

-

38

-

-

-

Accounts receivable from affiliated entity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

134

33

39

-

28

90

72

Prepaid expenses and other current assets

2,479

1,584

1,677

2,309

1,386

1,406

1,601

1,785

2,002

2,600

4,538

4,914

4,206

1,749

1,391

1,188

1,122

917

1,348

551

657

797

542

673

464

637

471

710

283

471

487

598

760

746

866

822

273

Prepaid expenses and other current assets from affiliated entities

1,790

1,050

1,581

1,100

1,441

1,120

2,107

1,787

1,674

1,846

997

1,251

1,816

1,512

1,697

1,882

1,538

610

634

1,045

2,017

1,382

1,482

473

1,657

2,057

573

763

832

887

686

813

400

441

346

992

653

Deferred tax asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

342

342

342

342

61

61

61

61

62

62

62

62

-

-

-

0

-

-

-

Total current assets

275,543

94,200

98,812

110,509

134,902

87,814

93,602

101,840

123,836

138,362

154,587

106,877

106,779

124,597

140,229

147,969

160,601

171,850

184,073

162,141

87,329

98,947

104,636

112,943

121,684

58,683

57,854

25,536

30,316

15,967

16,933

21,317

26,936

31,907

32,733

38,606

22,877

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

100

100

100

100

100

100

100

100

100

100

100

-

-

-

Fixed assets, net

12,104

12,773

13,516

14,265

15,185

15,949

16,228

16,868

17,486

18,320

18,471

15,017

9,803

9,025

8,990

8,700

8,393

7,306

6,458

5,497

4,946

4,583

4,634

4,549

3,021

2,886

2,290

348

362

363

391

421

355

295

288

306

276

Investment in affiliated entity - GeneOne

-

-

-

6,324

6,430

-

9,501

9,014

10,467

9,069

8,776

14,612

14,443

16,052

20,758

21,716

22,422

14,941

25,321

18,849

9,988

12,340

8,998

7,829

9,287

9,664

11,084

7,835

9,867

10,703

8,253

7,517

8,509

9,071

9,911

8,383

11,360

Investment in affiliated entities

21,210

6,315

-

2,157

2,225

9,405

3,198

2,667

-

2,325

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment in affiliated entity - PLS

21,210

6,315

-

2,157

2,225

9,405

3,198

2,667

3,307

2,325

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment in affiliated entity - PLS

-

-

-

-

-

-

-

-

-

-

2,720

3,339

3,027

3,777

4,537

5,309

5,026

5,045

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible assets, net

3,557

3,693

3,960

4,227

4,493

4,760

5,026

5,293

5,605

6,009

6,413

6,817

7,222

7,628

8,036

8,449

3,696

3,905

4,118

4,333

4,552

4,776

5,006

5,241

5,478

5,718

6,156

6,596

7,041

7,489

7,939

8,393

8,849

9,310

9,773

10,239

11,180

Goodwill

10,513

10,513

10,513

10,513

10,513

10,513

10,513

10,513

10,513

10,513

10,513

10,513

10,513

10,513

10,513

10,513

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

10,113

Operating lease right-of-use assets

13,511

13,783

14,002

14,222

14,432

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

88

186

259

550

591

881

1,410

717

244

265

266

267

520

509

294

100

237

-

-

Other assets

2,480

2,672

2,731

2,853

2,981

2,669

2,625

2,724

2,448

2,639

2,197

1,674

1,525

2,113

1,482

1,326

1,034

670

597

581

665

474

552

493

561

402

171

197

133

134

223

223

191

208

208

208

259

Total assets

338,920

143,951

151,533

165,073

191,165

131,113

140,696

148,923

173,664

187,239

203,680

158,853

153,314

173,707

194,549

203,985

211,288

213,840

230,771

201,702

117,855

131,785

134,532

142,152

151,657

88,287

88,015

50,992

58,201

45,138

44,476

48,595

55,350

61,106

63,266

67,857

56,067

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses

11,019

18,237

9,783

13,388

15,644

23,134

17,324

12,609

15,825

23,278

22,527

16,477

14,465

19,597

16,183

12,707

12,102

13,064

10,519

6,068

4,445

6,383

4,698

5,286

5,250

5,444

4,020

3,336

2,567

3,181

3,133

3,522

3,316

4,318

3,285

3,242

3,410

Accounts payable and accrued expenses due to affiliated entities

263

729

462

653

1,315

977

690

600

1,298

926

782

847

529

1,072

493

600

207

165

2,813

3,417

5

28

94

704

779

522

494

45

377

187

110

53

82

20

606

757

1,680

Accrued clinical trial expenses

5,061

4,049

-

-

-

5,671

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued clinical trial expenses

-

-

4,500

4,638

7,159

-

7,353

10,359

8,428

8,611

7,920

7,188

5,909

6,368

7,216

5,006

4,150

2,600

2,942

2,546

1,266

2,007

1,259

1,718

1,735

1,446

1,359

1,732

2,199

1,405

1,384

1,160

773

1,059

817

426

178

Common stock warrants

-

-

-

-

-

-

0

228

488

361

940

1,363

1,051

1,167

1,812

1,815

1,707

1,301

1,093

1,710

1,732

2,022

2,207

3,107

6,045

19,540

14,095

13,453

10,254

2,859

6,162

5,038

8,417

5,176

4,520

4,867

370

Deferred revenue

67

92

106

120

110

223

192

762

-

1,175

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue from affiliated entities

0

31

64

96

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

24,088

-

179

548

17,060

14,762

14,829

14,502

14,538

13,449

188

152

193

3,187

254

355

1,454

1,624

66

89

201

353

84

41

48

79

72

233

420

Deferred revenue from affiliated entities

-

-

-

-

2

33

68

55

56

174

243

274

368

407

438

469

376

504

523

432

376

394

413

432

376

388

401

413

376

388

401

413

376

388

401

413

375

Deferred rent

-

-

-

-

0

1,065

1,031

979

928

877

769

681

617

446

400

391

316

380

197

193

139

61

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability

2,132

2,074

2,011

1,949

1,888

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant funding liability

13,091

6,065

1,896

2,470

1,279

4,165

1,297

2,620

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant funding liability from affiliated entities

659

708

720

763

14

27

39

188

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-

-

-

-

-

-

-

-

261

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total current liabilities

32,294

31,989

19,546

24,079

27,415

35,299

27,998

28,406

51,375

35,405

33,363

27,381

40,002

43,823

41,374

35,494

33,398

31,466

18,277

14,519

8,158

14,085

8,927

11,603

15,641

28,966

20,437

19,071

15,978

8,376

11,276

10,230

13,014

11,043

9,703

9,941

6,436

Deferred revenue, net of current portion

100

101

124

116

141

150

192

175

-

215

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative liability

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative liability

22,041

8,819

4,503

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term Debt

-

-

-

62,757

60,562

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, net of current portion

-

-

-

-

-

-

-

-

203

-

164

205

227

317

365

374

434

103

12,798

313

329

173

2,898

2,738

2,315

1,997

1,724

85

86

88

90

77

79

80

81

66

72

Deferred revenue from affiliated entities, net of current portion

-

-

-

-

-

-

-

-

-

-

0

0

0

86

180

274

367

677

798

649

742

836

930

1,024

1,117

1,211

1,305

1,399

1,492

1,586

1,680

1,774

1,867

1,961

2,055

2,149

2,336

Deferred Rent Credit, Noncurrent

-

-

-

-

0

8,518

8,672

8,825

8,966

9,104

7,857

7,560

6,963

5,926

5,474

5,576

5,693

5,485

5,007

4,758

4,693

4,647

4,535

4,321

3,207

3,013

2,166

601

58

65

70

75

80

80

68

66

67

Operating lease liability, net of current portion

19,834

20,409

20,953

21,483

21,991

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred tax liabilities

32

32

26

26

24

24

24

24

24

24

174

-

-

174

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant funding liability from affiliated entity, net of current portion

135

135

135

81

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

73

36

50

50

64

87

99

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred tax liabilities

-

-

-

-

-

-

-

-

-

-

-

174

174

-

175

175

175

175

504

504

504

504

195

195

195

195

164

164

164

164

78

78

78

78

53

53

53

Total liabilities

151,066

138,546

115,414

108,595

110,199

44,080

36,987

37,431

60,570

44,750

41,560

35,323

47,368

50,328

47,571

41,895

40,070

37,907

37,385

20,745

14,429

20,247

17,488

19,884

22,477

35,384

25,799

21,321

17,780

10,281

13,195

12,236

15,121

13,244

11,962

12,276

8,966

Commitments and contingencies

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

-

-

0

Stockholders’ equity:
Inovio Pharmaceuticals, Inc. stockholders’ equity:
Preferred stock

0

0

0

0

0

0

0

0

0

0

0

0

-

0

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

-

-

0

Common stock

145

101

99

98

97

97

94

91

90

90

90

77

74

74

73

73

72

72

72

71

60

60

60

60

240

52

207

180

179

144

137

134

134

134

127

127

105

Additional paid-in capital

957,962

742,646

735,017

731,819

727,166

707,794

690,930

674,017

668,844

665,775

663,223

589,890

563,229

556,718

552,753

546,251

537,131

534,004

532,559

529,555

445,739

443,327

441,281

439,144

435,183

348,267

341,979

278,570

278,289

263,897

259,636

258,113

257,838

257,235

255,238

254,956

241,233

Accumulated deficit

-772,326

-739,785

-702,123

-679,032

-649,645

-620,426

-587,130

-562,114

-555,475

-523,356

-501,850

-467,715

-458,236

-434,838

-408,604

-387,845

-369,140

-361,097

-343,145

-348,740

-342,492

-331,910

-324,498

-317,321

-306,610

-295,788

-280,334

-249,456

-238,604

-229,760

-229,101

-222,479

-218,346

-210,091

-204,614

-200,073

-194,838

Accumulated other comprehensive income (loss)

-1,456

472

700

731

290

-528

-281

-598

-461

-117

559

1,180

781

1,327

2,659

3,514

2,909

2,708

3,654

-324

-191

-251

-110

-47

-71

-76

-98

-96

66

73

93

64

65

35

-5

-2

2

Total Inovio Pharmaceuticals, Inc. stockholders’ equity

184,324

3,435

33,693

53,616

77,909

86,936

103,612

111,395

112,998

142,392

162,022

123,433

105,849

123,282

146,881

161,993

170,971

175,687

193,139

180,562

103,116

111,226

116,732

121,836

128,741

52,455

61,755

29,197

39,932

34,354

30,764

35,833

39,692

47,314

50,745

55,007

46,502

Non-controlling interest

3,529

1,969

2,425

2,861

3,056

96

96

96

96

96

96

96

96

96

96

96

245

245

245

395

309

310

311

431

438

447

461

474

488

502

515

525

536

546

558

573

597

Total stockholders’ equity

187,854

5,404

36,118

56,478

80,966

87,032

103,709

111,491

113,094

142,488

162,119

123,529

105,945

123,378

146,978

162,089

171,217

175,933

193,385

180,957

103,426

111,537

117,044

122,268

129,179

52,902

62,216

29,671

40,420

34,857

31,280

36,359

40,229

47,861

51,303

55,581

47,100

Total liabilities and stockholders’ equity

338,920

143,951

151,533

165,073

191,165

131,113

140,696

148,923

173,664

187,239

203,680

158,853

153,314

173,707

194,549

203,985

211,288

213,840

230,771

201,702

117,855

131,785

134,532

142,152

151,657

88,287

88,015

50,992

58,201

45,138

44,476

48,595

55,350

61,106

63,266

67,857

56,067

GeneOne Life Sciences
Equity Securities, FV-NI

-

-

5,707

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other Assets, Noncurrent

-

-

338

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Plumbline Life Sciences
Equity Securities, FV-NI

-

-

2,289

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6.50% Convertible Senior Notes Due 2024
Convertible debt

63,730

64,180

62,119

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible Bonds [Member]
Convertible debt

12,825

12,842

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Korean Won Convertible Bonds Due 2024
Convertible debt

-

-

7,954

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-